Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
<b><i>Background:</i></b> Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis,...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/8/2664 |
| _version_ | 1797557465029541888 |
|---|---|
| author | Doan T. M. Ngo Trent Williams Sophie Horder Leonard Kritharides Janette Vardy Hiren Mandaliya Ina I. C. Nordman James Lynam Tony Bonaventura Aaron L. Sverdlov |
| author_facet | Doan T. M. Ngo Trent Williams Sophie Horder Leonard Kritharides Janette Vardy Hiren Mandaliya Ina I. C. Nordman James Lynam Tony Bonaventura Aaron L. Sverdlov |
| author_sort | Doan T. M. Ngo |
| collection | DOAJ |
| description | <b><i>Background:</i></b> Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associated with increased risks of adverse cardiovascular effects with bevacizumab have not been intensively studied. In this study, we determined factors associated with hospital admissions due to cardiovascular complications in patients who received bevacizumab for cancer treatment. <b><i>Methods and Results:</i></b> We retrospectively collected data for all patients treated with bevacizumab between the 1st January 2016 and the 31st December 2017 at the Hunter New England Local Health District. Patients’ characteristics and their medical history were obtained from hospital electronic medical records. Outcome data were sourced from the Institutional Cardiac and Stroke Outcomes Unit database. A total of <i>n</i> = 230 patients (mean age 65, males <i>n</i> = 124 (53.9%)) were treated with bevacizumab during the study period. <i>N</i> = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (<i>p</i> < 0.05), concomitant hypertension (<i>p</i> = 0.005), diabetes (<i>p</i> = 0.04), atrial fibrillation (<i>p</i> = 0.03), and lack of use of statin therapy (<i>p</i> = 0.03) were key contributors to hospital admission. <b><i>Conclusions:</i></b> Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications. |
| first_indexed | 2024-03-10T17:17:25Z |
| format | Article |
| id | doaj.art-a87038ac5c9a460aae70054bd5611b83 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T17:17:25Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-a87038ac5c9a460aae70054bd5611b832023-11-20T10:28:18ZengMDPI AGJournal of Clinical Medicine2077-03832020-08-0198266410.3390/jcm9082664Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with BevacizumabDoan T. M. Ngo0Trent Williams1Sophie Horder2Leonard Kritharides3Janette Vardy4Hiren Mandaliya5Ina I. C. Nordman6James Lynam7Tony Bonaventura8Aaron L. Sverdlov9School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, AustraliaHunter New England Local Health District, Newcastle, NSW 2305, AustraliaSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, AustraliaDepartment of Cardiology, Concord Repatriation General Hospital, Sydney Local Health District, Concord, NSW 2139, AustraliaFaculty of Medicine and Health, University of Sydney, Camperdown, NSW 2006, AustraliaHunter Cancer Research Alliance, Waratah, NSW 2298, AustraliaCalvary Mater Newcastle, Waratah, NSW 2298, AustraliaHunter New England Local Health District, Newcastle, NSW 2305, AustraliaCalvary Mater Newcastle, Waratah, NSW 2298, AustraliaHunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia<b><i>Background:</i></b> Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associated with increased risks of adverse cardiovascular effects with bevacizumab have not been intensively studied. In this study, we determined factors associated with hospital admissions due to cardiovascular complications in patients who received bevacizumab for cancer treatment. <b><i>Methods and Results:</i></b> We retrospectively collected data for all patients treated with bevacizumab between the 1st January 2016 and the 31st December 2017 at the Hunter New England Local Health District. Patients’ characteristics and their medical history were obtained from hospital electronic medical records. Outcome data were sourced from the Institutional Cardiac and Stroke Outcomes Unit database. A total of <i>n</i> = 230 patients (mean age 65, males <i>n</i> = 124 (53.9%)) were treated with bevacizumab during the study period. <i>N</i> = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (<i>p</i> < 0.05), concomitant hypertension (<i>p</i> = 0.005), diabetes (<i>p</i> = 0.04), atrial fibrillation (<i>p</i> = 0.03), and lack of use of statin therapy (<i>p</i> = 0.03) were key contributors to hospital admission. <b><i>Conclusions:</i></b> Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.https://www.mdpi.com/2077-0383/9/8/2664bevacizumabVEGF inhibitorscardiovascular riskcomplicationsoutcomes |
| spellingShingle | Doan T. M. Ngo Trent Williams Sophie Horder Leonard Kritharides Janette Vardy Hiren Mandaliya Ina I. C. Nordman James Lynam Tony Bonaventura Aaron L. Sverdlov Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab Journal of Clinical Medicine bevacizumab VEGF inhibitors cardiovascular risk complications outcomes |
| title | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
| title_full | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
| title_fullStr | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
| title_full_unstemmed | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
| title_short | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
| title_sort | factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab |
| topic | bevacizumab VEGF inhibitors cardiovascular risk complications outcomes |
| url | https://www.mdpi.com/2077-0383/9/8/2664 |
| work_keys_str_mv | AT doantmngo factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT trentwilliams factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT sophiehorder factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT leonardkritharides factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT janettevardy factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT hirenmandaliya factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT inaicnordman factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT jameslynam factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT tonybonaventura factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT aaronlsverdlov factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab |